截至2025年10月9日，楚昌投资持有公司股份362,525,962股（不含担保及信 托财产专户持有股份），持股比例为7.19%；"楚昌集团-国联民生保荐-22楚昌 EB01担保及信托财产专户"持有公司股份17,587,759股，持股比例为0.35%。本 次股票担保及信托登记解除后，上述担保及信托专户中的17,587,759股公司股份 将划转至楚昌投资证券账户，楚昌投资将持有公司股份380,113,721股（不含其他 两期可交换债券担保及信托财产专户持有股份），持股比例为7.54%；"楚昌集 1 团-国联民生保荐-22楚昌EB01担保及信托财产专户"将不再持有公司股份。本次 股票担保及信托登记解除后，公司控股股东及实际控制人不会发生变化，不构成 要约收购。 证券代码：600998 证券简称：九州通 公告编号：临 2025-069 九州通医药集团股份有限公司关于控股股东 完成2022年非公开发行可交换公司债券（第一期）兑付并 摘牌暨拟办理解除股票担保及信托登记的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 ...

Core Insights - The pharmaceutical commercial sector saw a slight increase of 0.17% on October 10, with Guofa Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Stock Performance - Guofa Co., Ltd. (600538) closed at 5.85, up 4.28% with a trading volume of 178,800 shares and a transaction value of 103 million yuan [1] - Other notable gainers included Dajia Weikang (301126) up 1.89%, Yingte Group (000411) up 1.77%, and Liuyao Group (603368) up 1.75% [1] - Conversely, the sector also experienced declines, with Saily Medical (603716) down 4.51% and Jianfa Zhixin (301584) down 4.01% [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 161 million yuan from institutional investors, while retail investors saw a net inflow of 214 million yuan [2] - The data indicates that while institutional investors were pulling back, retail investors were actively buying into the sector [2] Individual Stock Capital Flow - Shanghai Pharmaceuticals (601607) had a net inflow of 27.32 million yuan from institutional investors, while it faced a net outflow of 32.58 million yuan from speculative funds [3] - Dajia Weikang (301126) saw a net inflow of 4.95 million yuan from institutional investors, but also faced outflows from speculative funds [3] - Guofa Co., Ltd. (600538) had a net inflow of 4.07 million yuan from institutional investors, indicating some level of interest despite the overall outflow trend [3]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301015 | 百洋医药 | 27.17 | -2.96% | 5.74万 | 1.58亿 | | 301584 | C建发致 | 28.15 | -2.90% | 21.71万 | 6.15亿 | | 600833 | 第一医药 | 13.38 | -2.76% | 8.11万 | 260'T | | 301126 | 达嘉维康 | 11.13 | -2.37% | 4.04万 | 4537.69万 | | 603108 | 润达医疗 | 15.70 | -1.88% | 19.17万 | 3.00亿 | | 000705 | 浙江震元 | 9.78 | -1.41% | 13.46万 | 1.31亿 | | 002462 | 章章点 | 13.69 | -0.58% | 4.41万 | 6013.33万 | | 300937 | 药易购 | 26.53 | -0.49% | 1.29万 | 3415.25万 | | 600538 | 国发股份 ...

从资金流向上来看，当日医药商业板块主力资金净流入1486.86万元，游资资金净流出7521.88万元，散户 资金净流入6035.02万元。医药商业板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 301584 | C建发致 | 8225.62万 | 8.49% | -2828.35万 | -2.92% | -5397.28万 | -5.57% | | 600998 | 九州通 | 2389.11万 | 16.23% | -1071.49万 | -7.28% | -1317.63万 | -8.95% | | 600511 | 国药股份 | 895.78万 | 9.93% | -1003.50万 | -11.13% | 107.72万 | 1.19% | | 002589 | 瑞康医药 | 806.52万 | 19.20% | -436.26万 | -10.39% | -370.25万 | -8 ...

Core Insights - Hubei province is focusing on high-level opening up and enhancing its role as a market hub, with significant progress in trade and investment during the "14th Five-Year Plan" period [2][3][4] Trade and Economic Growth - Hubei's total retail sales increased from 1.8 trillion yuan in 2020 to 2.53 trillion yuan in 2024, with an average annual growth of 8.9% [3] - The province's import and export values have consistently crossed the thresholds of 500 billion, 600 billion, and 700 billion yuan from 2021 to 2024, achieving an average annual growth of 13.2% [3][4] - In the first eight months of 2025, Hubei's import and export growth reached 27.3%, the highest in Central China [3] Consumption and New Growth Drivers - The implementation of consumption upgrade policies has driven over 160 billion yuan in consumption, with significant growth in sectors like home appliances and new energy vehicles [3] - Online retail sales surged by 92.6% compared to the end of the "13th Five-Year Plan" [3] Foreign Trade and Market Expansion - Exports to countries involved in the Belt and Road Initiative increased by 131% compared to the end of the "13th Five-Year Plan," accounting for 53.3% of total exports [4] - The number of enterprises engaged in import and export activities rose to 9,570, with 14 enterprises exceeding 10 billion yuan in import and export value [4] Investment and Infrastructure Development - Hubei attracted 325 Fortune Global 500 companies, leading Central China in investment [5] - The province has established a comprehensive open platform system, including six comprehensive bonded zones and four bonded logistics centers [7] Logistics and Transportation - Hubei's logistics capabilities have been enhanced with the approval of the Huahu Airport as a comprehensive import port and the establishment of multiple international freight routes [7] - The province's highway network has surpassed 8,000 kilometers, achieving a significant milestone ahead of the "14th Five-Year Plan" targets [8]

Core Viewpoint - The announcement details the early release of share pledges by a major shareholder, Shanghai Hongkang, which may indicate improved financial stability and liquidity for the company [2][3]. Group 1: Share Pledge Release - Shanghai Hongkang has completed the early release of 73,000,000 shares, representing 1.45% of the company's total share capital [2]. - After the release, Shanghai Hongkang holds a total of 1,088,326,782 shares, which is 21.58% of the total share capital, with 466,571,892 shares still pledged, accounting for 42.87% of its holdings and 9.25% of the total share capital [2]. Group 2: Major Shareholder Pledge Situation - As of September 25, 2025, the controlling shareholder, Chuchang Investment, along with its concerted actors, holds 2,290,962,690 shares, which is 45.43% of the total share capital [2]. - Following the early release of shares, the total number of pledged shares held by Chuchang Investment and its concerted actors is 1,076,883,748 shares, reducing the pledged proportion of their holdings to 47.01% and the total share capital to 21.36% [2][3]. Group 3: Financial Stability - The controlling shareholder and its concerted actors have the financial capability to repay the pledged shares, with funding sources including bond issuance, dividends from the listed company, and investment income [3].

证券日报网讯 9月26日晚间，九州通发布公告称，公司股东上海弘康实业投资有限公司办理完成73， 000，000股（占公司总股本的1.45%）股份的提前解除质押手续。 （文章来源：证券日报） ...

Group 1 - The company Jiuzhoutong (SH 600998) announced that its shareholder Shanghai Hongkang holds approximately 1.088 billion shares, accounting for 21.58% of the total share capital [1] - After the early release of share pledges, Shanghai Hongkang has pledged a total of approximately 467 million shares, which is 42.87% of its holdings and 9.25% of the total share capital [1] - As of September 25, 2025, the controlling shareholder Chuchang Investment and its concerted parties hold approximately 2.291 billion shares, representing 45.43% of the total share capital [1] Group 2 - Following the early release of share pledges, the total number of pledged shares held by Chuchang Investment and its concerted parties is approximately 1.077 billion shares, reducing the pledged proportion of their holdings to 47.01% and the total share capital to 21.36% [1] - For the first half of 2025, Jiuzhoutong's revenue composition is as follows: pharmaceutical wholesale and related businesses account for 95.94%, pharmaceutical manufacturing for 1.96%, pharmaceutical retail for 1.84%, medical health and technology services for 0.17%, and other businesses for 0.08% [1] - As of the report date, Jiuzhoutong's market capitalization is 24.6 billion yuan [1]

重要内容提示： ●公司股东上海弘康办理完成73,000,000股的股份提前解除质押手续，本次解除质押 股份占其所持股份的比例为6.71%，占公司总股本的比例为1.45%。 ●公司股东上海弘康持有公司股份1,088,326,782股，占公司总股本的比例为21.58%。 本次股份提前解除质押办理完成后，上海弘康累计质押公司股份466,571,892股，占其所 持股份的比例为42.87%，占公司总股本的比例为9.25%。 ●截至2025年9月25日，控股股东楚昌投资及其一致行动人合计持有公司股份 2,290,962,690股，占公司总股本的比例为45.43%。本次股份提前解除质押办理完成后， 控股股东楚昌投资及其一致行动人所持公司股份中已质押的股份总数为1,076,883,748股， 占其所持股份的比例下降至47.01%，占公司总股本的比例下降至21.36%。 证券代码：600998 证券简称：九州通 公告编号：临 2025-068 九州通医药集团股份有限公司 关于股东提前解除股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律 ...

Group 1 - Hubei Jiuyuan Biomedical Technology Co., Ltd. has been established with a registered capital of 30 million yuan [1] - The legal representative of the company is Lü Xiaowan [1] - The business scope includes sales of Class I medical devices, sales of pre-packaged health food, general equipment repair, specialized equipment repair, and non-residential real estate leasing [1] Group 2 - The company is wholly owned by Jiuzhoutong Medical Device Group Co., Ltd., a subsidiary of Jiuzhoutong (600998) [1]